1/12/2009

Dutch and German researchers found that children with a subtype of acute lymphoblastic leukemia who have the BCR-ABL1 fusion gene are more prone to relapse than patients without the gene. The finding suggests that carriers of the gene should get more intensive treatment with medicines already on the market "or with new, more-targeted drugs for which the biology of the BCR-ABL1-like subtype needs further study," the lead scientist said.

Full Story:
Yahoo!

Related Summaries